Tanase Alina, Tomuleasa Ciprian, Marculescu Alexandra, Bardas Alexandru, Colita Anca, Orban Carmen, Ciurea Stefan Octavian
Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Acta Haematol. 2016;135(4):211-6. doi: 10.1159/000443469. Epub 2016 Feb 26.
Haploidentical stem cell transplantation is a therapeutic option for patients without an HLA-matched donor. It is increasingly being used worldwide due to the application of posttransplantation cyclophosphamide and is associated with lower incidence of graft-versus-host disease and treatment-related mortality. Haploidentical donors are generally available for most patients and stem cells can be rapidly obtained. Delays in transplantation while waiting for unrelated donor cells can be potentially problematic for patients with advanced disease at risk for progression; thus, the use of haploidentical donors, especially in this setting, can be life-saving. Here we reviewed the literature on haploidentical stem cell transplantation performed with posttransplantation cyclophosphamide.
单倍体相合干细胞移植是没有 HLA 匹配供者的患者的一种治疗选择。由于移植后环磷酰胺的应用，它在全球范围内越来越多地被使用，并且与移植物抗宿主病的发生率降低以及治疗相关死亡率降低相关。大多数患者通常都能找到单倍体相合供者，并且可以快速获得干细胞。对于有疾病进展风险的晚期患者，等待无关供者细胞时移植延迟可能会有潜在问题；因此，使用单倍体相合供者，尤其是在这种情况下，可能会挽救生命。在此，我们回顾了关于采用移植后环磷酰胺进行单倍体相合干细胞移植的文献。
